Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03054896 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R or R-CHOP for Patients With Richter's Syndrome
A Phase 2 study of Richter Syndrome, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 69
- Enrollment target
- 3
- Study locations
NCT03054896: Active Phase 2 study of Richter Syndrome, sponsored by Dana-Farber Cancer Institute.
NCT03054896 is a Phase 2 study of Richter Syndrome that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 69 participants, above the 26-participant average among 12 other Richter Syndrome trials with a reported enrollment target (165% higher). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03054896, a Phase 2 study of Richter Syndrome, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 69 participants
- Enrollment target
- 3
- Study locations
Study Summary
This research study is evaluating the combination of a study drug, venetoclax, and a standard chemotherapy regimen, R-EPOCH or R-CHOP, as a possible treatment for Richter's Syndrome. The drugs involved in this study are: * Venetoclax * R-EPOCH: * Rituximab * Etoposide * Prednisone * Vincristine Sulfate (Oncovin) * Cyclophosphamide * Doxorubicin Hydrochloride (Hydroxydaunomycin) * R-CHOP: * Rituximab * Cyclophosphamide Vincristine * Doxorubicin Hydrochloride (Hydroxydaunomycin) * Sulfate (Oncovin) * Prednisone
Primary Outcome
The CRR is defined as the proportion of participants achieving complete remission (CR) or complete remission with incomplete hematologic recovery (CRi) based on 2008 IW-CLL Response Criteria.
Conditions Studied
Interventions
- DRUG Venetoclax
- OTHER DA-EPOCH-R
- OTHER R-CHOP
Study Locations (3)
Massachusetts
- Dana Farber Cancer Institute - Boston
Ohio
- Ohio State University - Columbus
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2017-03-08 |
| Est. Completion | 2027-12-01 |
| Phase | Phase 2 |
What the registry record for NCT03054896 still lists
NCT03054896 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 69 participants, a relatively small participant target, above the 26-participant average among 12 other Richter Syndrome trials with a reported enrollment target (165% higher).
The record links to 1 condition, with Richter Syndrome appearing as the primary indexed condition, and to 3 interventions - of which Venetoclax is the first listed.
NCT03054896 reports a single indexed study location in Massachusetts, Ohio, Texas.
Frequently Asked Questions
What is clinical trial NCT03054896 about?
NCT03054896 is a clinical study titled "A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R or R-CHOP for Patients With Richter's Syndrome". This research study is evaluating the combination of a study drug, venetoclax, and a standard chemotherapy regimen, R-EPOCH or R-CHOP, as a possible treatment for Richter's Syndrome. The drugs involved in this study are: * Venetoclax * R-EPOCH: * Rituximab * Etoposide * Prednisone * Vincr...
What is the current status of trial NCT03054896?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 69 participants. The study started on 2017-03-08. Estimated completion is 2027-12-01.
What conditions does trial NCT03054896 study?
This clinical trial studies the following conditions: Richter Syndrome.
What interventions are being tested in trial NCT03054896?
The interventions under investigation include: Venetoclax (DRUG), DA-EPOCH-R (OTHER), R-CHOP (OTHER).
Who is sponsoring clinical trial NCT03054896?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03054896 being conducted?
This trial has 3 study locations across Massachusetts, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Richter Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03054896's enrollment target sits among peer trials
69 1st of 12 higher than 12 of 12 other Richter Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Richter Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation
RECRUITING · Phase 2
-
Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype
RECRUITING · Phase 2
-
Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
RECRUITING · Phase 2
-
Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation
RECRUITING · Phase 2
-
Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome
ACTIVE NOT RECRUITING · Phase 2
-
Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04020575 · 69 participants · Phase 1
Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)
- NCT04163614 · 69 participants · NA
Blood Pressure Slopes and Ultrafiltration in Hemodialysis Patients
- NCT04164641 · 69 participants · NA
Noraxon myoRESEARCH™ Software Gait Analysis Evaluation and Orthotic Gait Correction in Reducing Diabetic Foot Ulceration Or Subsequent Amputation in Patients With a History of a Diabetic Foot Ulceration
- NCT04493372 · 69 participants · NA
Deciphering Preserved Autonomic Function After Spinal Cord Injury
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI